Last reviewed · How we verify
Nicotine 0%
Nicotine 0% is a nicotine-free formulation that may serve as a placebo or behavioral substitute in smoking cessation or nicotine dependence research.
Nicotine 0% is a nicotine-free formulation that may serve as a placebo or behavioral substitute for nicotine dependence without delivering active nicotine. Used for Smoking cessation support (behavioral component).
At a glance
| Generic name | Nicotine 0% |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Texas at Austin |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
This product appears to be a non-active formulation containing no nicotine, likely used as a control or placebo comparator in clinical research settings. It may be designed to provide behavioral or sensory substitution (e.g., oral habit replacement) without delivering active nicotine, allowing researchers to isolate the pharmacological effects of nicotine from psychological or behavioral components of smoking or nicotine use.
Approved indications
- Smoking cessation (research/control use)
- Nicotine dependence (research comparator)
Common side effects
Key clinical trials
- Effects of Tobacco Abuse Liability-dependent Taxes in the ETM (NA)
- The Use of tDCS for Vaping Reduction (NA)
- Primary Connections for Youth and Families (NA)
- ACT_for Alcohol Use Disorder and Depression (NA)
- Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events (PHASE1)
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer (NA)
- Smart Olfaction App to Reduce Relapse (EARLY_PHASE1)
- Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction - Beta Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine 0% CI brief — competitive landscape report
- Nicotine 0% updates RSS · CI watch RSS
- University of Texas at Austin portfolio CI